You are here: Industry Insights > NICE

News List

NICE approves Bayer’s liver cancer drug pharmaphorum
November 30, 2018
NICE has given Bayer’s advanced liver cancer therapy Stivarga (regorafenib) the go-ahead after it undertook a rapid review following earlier guidance that rejected the drug......
NICE recommends Bayer's Stivarga for advanced hepatocellular carcinoma pharmafile
November 30, 2018
The National Institute for Health and Care Excellence (NICE) has voiced its recommendation for Bayer’s Stivarga (regorafenib) for use on the NHS in England and Wales in the treatment of advanced unresectable hepatocellular carcinoma (HCC)...
Bayer’s Stivarga wins NICE backing for advanced liver cancer pharmatimes
November 29, 2018
Bayer’s Stivarga has been recommended for use on the NHS by the National Institute for Health and Care Excellence (NICE) following a rapid review of guidance published earlier in the year which rejected the drug.
Thousands to benefit as NHS funds Keytruda lung cancer combo pharmaphorum
November 26, 2018
NICE has said MSD’s cancer immunotherapy, Keytruda, should receive interim funding on the NHS in certain patients with untreated lung cancer, in combination with chemotherapy.
NHS England appoves Gilead's CAR T therapy Yescarta pharmafile
November 20, 2018
Gilead’s CAR T therapy Yescarta is set to be made available on the NHS in England for adults with aggressive non-Hodgkin lymphoma, it was announced today.
MSD's Keytruda to treat melanoma in England on the Cancer Drugs Fund pharmafile
November 20, 2018
MSD’s blockbuster immunotherapy Keytruda (pembrolizumab) will now be made available to patients in England via the Cancer Drugs Fund, it has emerged.
NICE fail to recommend AstraZeneca's cancer drug Olaparib on cost effectiveness basis pharmatimes
November 12, 2018
Britain’s cost effectiveness body the National Institute of Health and Care Excellence (NICE) has chosen not to recommend AstraZeneca’s Olaparib for women
NICE recommends Vyxeos for specific secondary AML biospectrumasia
November 12, 2018
Vyxeos is an advanced liposomal formulation that delivers a synergistic molar ratio of daunorubicin and cytarabine
NICE recommends Jazz Pharmaceuticals’ Vyxeos to treat AML pharmaceutical-technology
November 12, 2018
The UK’s National Institute for Health and Care Excellence (NICE) has recommended Jazz Pharmaceuticals’ Vyxeos formulation to treat adults with two types of secondary Acute Myeloid Leukaemia (AML).
NICE recommends Jazz Pharmaceuticals’ Vyxeos to treat AML pharmaceutical-technology
November 10, 2018
The UKs National Institute for Health and Care Excellence (NICE) has recommended Jazz Pharmaceuticals Vyxeos formulation

Previous page 1 2 3 4 5 6 7 8 9 10 ... 41 42 Next page